Search PubMed⌕ Search

Biomedical subjects

T Agishi

Publications and source records attributed to T Agishi.

At least 127 records · Page 7Linked to original sources
PubMed1988

(Pyridoxylated hemoglobin)-(polyoxyethylene) conjugate solution as blood substitute for normothermic whole body rinse-out.

In order to investigate a new possibility for artificial blood with oxygen-carrying capability to be applied to other than mere supplementation, normothermic whole body rinse-out in which artificial blood deriving from perfluorochemical emulsion, Fluosol-DA 20% (Green Cross Co., Ltd., Osaka, Japan) or stabilized hemoglobin solution, (pyridoxylated hemoglobin)-(polyoxyethylene) conjugate solution (Ajinomoto Co., Ltd., Tokyo, Japan) were used as rinsing fluid for a blood purification experiment. Replacement either with approximately 150 ml/kg of Fluosol-DA or stabilized hemoglobin solution showed effective removal of digoxin at a reduction rate of 96.3% or 92.2%, respectively. However, when Fluosol-DA was used, a certain amount of perfluorochemical should be retrieved by centrifugation to avoid a possible toxic effect on the reticulo-endothelial system. Even though 3 out of 6, and 3 out of 8 dogs, respectively, survived for a long period after the procedure, the experimental dogs were very susceptible to infection.

Animals↗
PubMed1988

Long term liver preservation using artificial blood substitutes.

Twenty-four hour hypothermic perfusion preservation of the liver was aimed using an artificial blood substitutes. A canine liver was harvested and preserved using originally designed perfusates. In group 1, Perfluorotributylamine solution (Oxypherol solution) was used. In group 2, (Pyridoxylated hemoglobin)-(Polyoxyethylene) conjugate solution (Stabilized Hemoglobin, PHP-1). In group 3 and in group 4, modified Stabilized hemoglobin, PHP-3 and PHP-4 was used. After the preservation, each liver was transplanted orthotopically. Postoperative graft function was estimated the following parameter, such as bile excretion, consciousness level, activated clotting time, and survival rate. In group 1 and group 2, improvement of such factors were not fully observed. On the contrary, in group 3 and 4, complete recovery of the function was seen and in group 4, longer survival was obtained. PHP solution was considered suitable perfusate for liver preservation.

Animals↗
PubMed1988

Effect of membrane trapping in plasma fractionator on separative characteristics.

Several kinds of plasma fractionators have been introduced to actively separate protein fractions between albumin and globulins in double filtration plasmapheresis. However, relatively large molecular weight proteins are known to be partially trapped by the membrane in a plasma fractionator. In this paper, effects of membrane trapping on separation characteristics in plasma fractionators were examined during in vitro and in vivo studies. All in vitro experiments were done with a closed circuit under constant-flow rate filtration. Protein concentration in feed tank kept constant at no filtration in AS-14H, Evaflux 4A and 2A, while 20-40% of IgG and 40-60% of beta-lipoprotein in 2 liter plasma were removed by membrane trapping for 300 min when filtration fraction equaled 0.87. Protein plugging to the membrane seems to be a major factor in these proteins. And, Dead-end and Partially Discarded modalities with relatively high filtration fraction are effective for the separation between albumin and globulin. Twenty-seven DFPP treatments in 13 patients with autoimmune diseases were done to allow us to estimate the effects of membrane trapping during an in vivo study. All treatments using 6 types of plasma fractionator were performed under constant operating conditions with Partially Discarded modality. In any plasma fractionator, beta-lipoprotein was fairly trapped at 30 min after the start of treatment.

Adsorption↗
PubMed1987

[Implantation of a vascular access device in cancer treatment: operation or angiographic technic?].

Thirty cancer patients, who were diagnosed to be beyond the operable stage, were treated by intra-arterial anticancer agent infusion via an implantable vascular access device (VAD) combined with local hyperthermia and/or charcoal hemoperfusion. The VAD was implanted by a surgical procedure in 14 patients, or by a technique similar to super-selective angiography mainly via the femoral artery in the remaining 16 patients who could not be operated on because of their seriously severe clinical condition and/or the difficulty involved in approaching the tumor feeding artery due to the presence of huge tumors or multiple lymph node metastasis. No serious complications were seen in these treatments. However, the catheter became occluded after an average post-implantation period of 9 months in 6 patients in the operative group. Since an operative procedure is very often too invasive for end-stage cancer patients and may enhance tumor growth, VAD implantation utilizing an angiographic technique is recommendable for the treatment of advanced cancer.

Adult↗
PubMed1987

[Continuous intra-arterial infusion chemotherapy by implantable catheter access connected with a continuous infusion pump].

Eleven non-resectable cancer patients have been successfully treated by means of a one-shot and continuous intra-arterial infusion chemotherapy, utilizing an implantable vascular access device (Catheter Access) connected to a continuous infusion pump (Nipro portable syringe infusion pump) via a non-corning needle (Nipro coreless needle set). This result suggests that this simple and inexpensive method can be applied not only for cancer chemotherapy but also for intravenous hyper-alimentation and for treatment of epidural anesthesia.

Aged↗
PubMed1986

[Combination of selective intra-arterial infusion of an anticancer agent via the vascular access port with RF local hyperthermia].

It is desirable for multidisciplinary cancer treatments to be concentrated as selectively as possible onto the cancer-bearing organs in order to augment the anticancer effects and minimize the untoward effects. Combined treatments of selective intraarterial infusion of anticancer agents via an implanted Vascular Access Port with local hyperthermia using 13.56 MHz RF have been performed in 12 patients with extensive cancers. In 9 out of these 12 cases (75%), more than 50% reduction in tumor size has been obtained. Tumor-diminishing effect was more remarkable in patients who underwent bolus infusion of anticancer agents such as 1 mg/kg of mitomycin C under charcoal hemoperfusion for rapid removal of anticancer agents from the blood stream.

Aged↗
PubMed1986

[Intraarterial bolus infusion followed by rapid removal of anticancer agents with hemocarboperfusion under local hyperthermia in advanced hepatic cancer].

Reported herein is a new multidisciplinary treatment modality for unresectable hepatic cancer in which local hyperthermia and intraarterial infusion of bolus anticancer agent are simultaneously undertaken while anticancer agent leaking from the hepatic bed into the general circulation is rapidly removed by charcoal hemoperfusion. Local hyperthermia induced by exposure to 13.56-MHz radiofrequency waves was conducted between one and one and a half hours once or twice a week. During the hyperthermia treatment, a bolus of either 1 mg/kg Mitomycin C or 2 mg/kg Adriamycin was injected into the hepatic artery via a Vascular Access Port, the catheter portion of which had been surgically inserted into the hepatic artery and the reservoir of which had been implanted subcutaneously. In general, a regular dose of 6 mg of Mitomycin C was injected into the Vascular Access Port during the following hyperthermia procedures. In seven of nine patients (78%) treated with this method, a marked reduction in tumor size of more than 50% was observed on computed tomograms. A light to moderate degree of side effects such as leukocytopenia, thrombocytopenia, liver dysfunction or hair loss were noticed after the bolus infusion, but were not so serious as to threaten the patients' lives.

Adult↗